Autoimmune & Inflammatory Diseases (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn’s Disease (CD), Ulcerative Colitis (UC), Psoriasis (PsO))

TNF-alpha Inhibitors

● Infliximab (Remicade®, Inflectra®, Renflexis®) 

● Golimumab (Simponi Aria®) 

● Certolizumab pegol (Cimzia®) (though often subcutaneous)

IL-6 Inhibitors

● Tocilizumab (Actemra®) 

● Sarilumab (Kevzara®) (subcutaneous, but sometimes infused in special cases)

B-Cell Depleting Agents

● Rituximab (Rituxan®, Truxima®, Ruxience®) 

IL-17/IL-23 Inhibitors

● Ustekinumab (Stelara®) (initially IV, then subcutaneous)

Integrin Receptor Antagonists

● Vedolizumab (Entyvio®) 

● Natalizumab (Tysabri®) 

Neurology (Multiple Sclerosis, Myasthenia Gravis, NMOSD)

B-Cell Depletion

● Ocrelizumab (Ocrevus®) 

● Rituximab (Rituxan®) 

Complement Inhibitors

● Eculizumab (Soliris®) 

● Ravulizumab (Ultomiris®) 

Osteoporosis - RANK Ligand Inhibitor

● Denosumab (Prolia®, Xgeva®) (Usually subcutaneous but sometimes IV)

Respiratory (Asthma, COPD) - IgE Inhibitor

● Omalizumab (Xolair®) (usually subcutaneous but sometimes IV)

Oncology (Cancer Treatments) - Monoclonal Antibodies & Targeted Therapies

CD20-targeted (B-cell cancers, lymphomas)

● Rituximab (Rituxan®) 

● Obinutuzumab (Gazyva®) 

● Ofatumumab (Arzerra®) 

HER2-targeted (Breast, Gastric Cancers)

● Trastuzumab (Herceptin®, Ogivri®, Herzuma®)

● Pertuzumab (Perjeta®) (Often given with trastuzumab)

EGFR-targeted (Colorectal, Head & Neck Cancers)

● Cetuximab (Erbitux®)

● Panitumumab (Vectibix®) (Usually subcutaneous but sometimes IV)

VEGF/VEGFR Inhibitors (Various cancers)

● Bevacizumab (Avastin®) 

● Ramucirumab (Cyramza®) 

Checkpoint Inhibitors (Immunotherapy)

● Pembrolizumab (Keytruda®)

● Nivolumab (Opdivo®) 

● Atezolizumab (Tecentriq®) 

Hematology (Blood Disorders)

Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)

● Eculizumab (Soliris®)

● Ravulizumab (Ultomiris®)

Hemophilia (Factor Replacement)

● Emicizumab (Hemlibra®) (Usually subcutaneous but sometimes IV)

Infectious Diseases - COVID-19 (Monoclonal Antibodies)

● Bamlanivimab + Etesevimab 

● Casirivimab + Imdevimab (REGEN-COV®)

Rare Diseases - Enzyme Replacement Therapies

● Elosulfase alfa (Vimizim®) 

● Idursulfase (Elaprase®)